NEW ORLEANS -- Brexpiprazole (Rexulti) helped ease agitation in people with Alzheimer's dementia, according to a phase III study. Over the course of the 12-week trial, patients on either a 2-mg or ...

The advisory committee voted 10-1 against recommending brexpiprazole in combination with sertraline for PTSD based on the lack of efficacy. The Food and Drug Administration’s (FDA) Psychopharmacologic ...

The recommended dose of the drug is 2mg/day with 0.5mg or 1mg as the starting dose for the treatment of major depressive disorder, while a dose of 2mg to 4mg/day can be used for the treatment of ...

Review the side-effects of Brexpiprazole as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

FDA advisors voted in favor of brexpiprazole (Rexulti) for treating agitation associated with Alzheimer's dementia (AAD), despite increased mortality risk. By a vote of 9-1 on Friday, members of the ...

For many people living with dementia and their caregivers, the worst symptom of the disease is not memory loss, but agitation. Whether it comes out as verbal insults or physical violence, agitation in ...

According to the letter, the application could not be approved due to lack of substantial efficacy from the submitted studies. The Food and Drug Administration (FDA) has issued a Complete Response ...

In a randomized clinical trial, researchers determined whether brexpiprazole is an efficacious, safe, and well-tolerated treatment for agitation in patients with Alzheimer dementia. Brexpiprazole, 2 ...

SAN FRANCISCO--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc., (Otsuka) and Lundbeck US (Lundbeck) today presented positive efficacy and safety data from multiple Phase 3 studies of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with agitation in Alzheimer’s dementia were ...

Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older 1 Approval follows a positive Committee for Medicinal Products for ...